Key highlights
- Novo Nordisk completed the acquisition of Akero for $4.7 billion.
- A $0.5 billion Contingent Value Right is tied to EFX approval for MASH treatment.
- Akero is now a wholly owned subsidiary and delisted from Nasdaq.
Acquisition Completion
Novo Nordisk has finalized its acquisition of Akero Therapeutics, initially announced on October 9, 2025. The transaction involved purchasing all outstanding shares of Akero for $54 per share, totaling an aggregate value of $4.7 billion.
Contingent Value Right
As part of the deal, a non-transferable Contingent Value Right (CVR) was included. This CVR entitles holders to an additional $6 per share, amounting to $0.5 billion, contingent upon U.S. regulatory approval of Akero's lead candidate, EFX, for treating compensated cirrhosis due to MASH.
Subsidiary Status
Following the acquisition, Akero has become a wholly owned subsidiary of Novo Nordisk. Consequently, Akero's common stock will no longer be listed or traded on the Nasdaq Global Select Market.
